SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Emmaus Life Sciences, Inc. – ‘10-K’ for 9/30/16 – ‘EX-31.2’

On:  Thursday, 12/22/16, at 5:04pm ET   ·   For:  9/30/16   ·   Accession #:  1615774-16-9049   ·   File #:  1-35527

Previous ‘10-K’:  ‘10-K’ on 1/5/16 for 9/30/15   ·   Next:  ‘10-K’ on 12/29/17 for 9/30/17   ·   Latest:  ‘10-K’ on 3/31/23 for 12/31/22   ·   4 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/22/16  Emmaus Life Sciences, Inc.        10-K        9/30/16   71:6.7M                                   S2 Filings LLC/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    882K 
 2: EX-3.1      Articles of Incorporation/Organization or Bylaws    HTML    105K 
 3: EX-4.4      Instrument Defining the Rights of Security Holders  HTML     35K 
 4: EX-4.5      Instrument Defining the Rights of Security Holders  HTML     51K 
 5: EX-4.6      Instrument Defining the Rights of Security Holders  HTML     50K 
 6: EX-10.23    Material Contract                                   HTML     35K 
 7: EX-10.24    Material Contract                                   HTML     59K 
 8: EX-21.1     Subsidiaries List                                   HTML     17K 
 9: EX-23.1     Consent of Experts or Counsel                       HTML     19K 
10: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
11: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
12: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
13: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
20: R1          Document and Entity Information                     HTML     49K 
21: R2          Consolidated Balance Sheets                         HTML    110K 
22: R3          Consolidated Balance Sheets (Parenthetical)         HTML     40K 
23: R4          Consolidated Statements of Operations               HTML     70K 
24: R5          Consolidated Statements of Changes in               HTML     63K 
                Stockholders' Deficit                                            
25: R6          Consolidated Statements of Cash Flows               HTML    100K 
26: R7          Nature of Operations                                HTML     41K 
27: R8          Summary of Significant Accounting Policies          HTML     66K 
28: R9          Convertible Debt and Equity Financings              HTML    136K 
29: R10         Derivative Liabilities                              HTML     59K 
30: R11         Stockholders' Deficit                               HTML    127K 
31: R12         Income Taxes                                        HTML     45K 
32: R13         Related Party Transactions                          HTML     40K 
33: R14         Loss Per Share                                      HTML     36K 
34: R15         Commitments and Contingent Liabilities              HTML     55K 
35: R16         Significant Customers                               HTML     25K 
36: R17         Subsequent Events                                   HTML     41K 
37: R18         Summary of Significant Accounting Policies          HTML    125K 
                (Policies)                                                       
38: R19         Summary of Significant Accounting Policies          HTML     28K 
                (Tables)                                                         
39: R20         Convertible Debt and Equity Financings (Tables)     HTML    114K 
40: R21         Derivative Liabilities (Tables)                     HTML     50K 
41: R22         Stockholders' Deficit (Tables)                      HTML    103K 
42: R23         Income Taxes (Tables)                               HTML     43K 
43: R24         Loss Per Share (Tables)                             HTML     33K 
44: R25         Commitments and Contingent Liabilities (Tables)     HTML     34K 
45: R26         Nature of Operations (Details Narrative)            HTML     62K 
46: R27         Summary of Significant Accounting Policies          HTML     30K 
                (Details)                                                        
47: R28         Summary of Significant Accounting Policies          HTML     75K 
                (Details Narrative)                                              
48: R29         Convertible Debt and Equity Financings (Details)    HTML    110K 
49: R30         Convertible Debt and Equity Financings (Details     HTML    105K 
                Narrative)                                                       
50: R31         Derivative Liabilities (Details)                    HTML     30K 
51: R32         Derivative Liabilities (Details 1)                  HTML     57K 
52: R33         Derivative Liabilities (Details Narrative)          HTML     86K 
53: R34         Stockholders' Deficit (Details)                     HTML     28K 
54: R35         Stockholders' Deficit (Details 1)                   HTML     42K 
55: R36         Stockholders' Deficit (Details 2)                   HTML    100K 
56: R37         Stockholders' Deficit (Details 3)                   HTML     45K 
57: R38         Stockholders' Deficit (Details 4)                   HTML     50K 
58: R39         Stockholders' Deficit (Details Narrative)           HTML    203K 
59: R40         Stockholders' Deficit (Details Narrative 1)         HTML     55K 
60: R41         Income Taxes (Details)                              HTML     37K 
61: R42         Income Taxes (Details 1)                            HTML     42K 
62: R43         Income Taxes (Details Narrative)                    HTML     25K 
63: R44         Related Party Transactions (Details Narrative)      HTML     88K 
64: R45         Loss Per Share (Details)                            HTML     39K 
65: R46         Commitments and Contingent Liabilities (Details)    HTML     56K 
66: R47         Commitments and Contingent Liabilities (Details     HTML    107K 
                Narrative)                                                       
67: R48         Significant Customers (Details Narrative)           HTML     30K 
68: R49         Subsequent Events (Details Narrative)               HTML    109K 
70: XML         IDEA XML File -- Filing Summary                      XML    111K 
69: EXCEL       IDEA Workbook of Financial Reports                  XLSX     89K 
14: EX-101.INS  XBRL Instance -- myan-20160930                       XML   2.01M 
16: EX-101.CAL  XBRL Calculations -- myan-20160930_cal               XML    143K 
17: EX-101.DEF  XBRL Definitions -- myan-20160930_def                XML    731K 
18: EX-101.LAB  XBRL Labels -- myan-20160930_lab                     XML   1.10M 
19: EX-101.PRE  XBRL Presentations -- myan-20160930_pre              XML    922K 
15: EX-101.SCH  XBRL Schema -- myan-20160930                         XSD    169K 
71: ZIP         XBRL Zipped Folder -- 0001615774-16-009049-xbrl      Zip    163K 


‘EX-31.2’   —   Certification — §302 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 

Exhibit 31.2

 

Certification of Principal Financial Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

 

I, Paul Buck, certify that:

 

  1. I have reviewed this Form 10-K of MYnd Analytics, Inc. for the fiscal year ended September 30, 2016;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

  

December 22, 2016 /s/ Paul Buck
  Name: Paul Buck
  Title: Chief Financial Officer (Principal Financial Officer)

 

 C: 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:12/22/168-K
For Period end:9/30/16
 List all Filings 


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/31/22  Emmaus Life Sciences, Inc.        10-K       12/31/21   98:18M                                    ActiveDisclosure/FA
 8/10/21  Emmaus Life Sciences, Inc.        10-K/A     12/31/20   92:18M                                    ActiveDisclosure/FA
 5/04/21  Emmaus Life Sciences, Inc.        10-K       12/31/20   97:18M                                    ActiveDisclosure/FA
 1/25/21  Emmaus Life Sciences, Inc.        10-K       12/31/19  121:29M                                    ActiveDisclosure/FA
Top
Filing Submission 0001615774-16-009049   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 7:00:04.1am ET